液態切片(液態生物檢體)的全球市場 - 成長，趨勢，預測(2019年∼2024年)
Fluid Biopsy Market - Growth, Trends, and Forecast (2019 - 2024)
|出版商||Mordor Intelligence LLP||商品編碼||391417|
|出版日期||內容資訊||英文 113 Pages
|液態切片(液態生物檢體)的全球市場 - 成長，趨勢，預測(2019年∼2024年) Fluid Biopsy Market - Growth, Trends, and Forecast (2019 - 2024)|
|出版日期: 2019年05月01日||內容資訊: 英文 113 Pages||
Cancer prevalence data indicate the number of people diagnosed with cancer in their lifetime. The key facts stated by WHO estimates that cancer is the second leading cause of mortality across the globe, with around 14 million new cases and 8.2 million cancer-related deaths in 2012, and 8.8 million deaths in 2015. The number of new cases is expected to rise by about 70% in the next two decades. By 2030, the global burden is expected to grow to 21.7 million new cancer cases and 13 million cancer deaths, which can be attributed to the aging of the population. The future burden is expected to be even larger, because of the adoption of western lifestyles, such as smoking, poor diet, physical inactivity, and fewer childbirths, in economically developing countries. The demand for early detection of cancer is poised to influence the growth of the global market. Liquid biopsy has been in great demand in the diagnosis of solid and other tumors. Various cancers, such as non-small cell lung carcinoma, head and neck cancer, breast cancer, lymphomas, leukemia, and breast and liver cancer, can be diagnosed early with the help of liquid biopsy. These are the five most common forms of cancer that affect the global population. Lung cancer is the most common variety of cancer, accounting for almost a fifth (17%) of all cases diagnosed. An estimated 6.7 million women worldwide, are believed to have been already diagnosed or bearing a risk of developing breast cancer. Bowel, stomach, and liver cancer have also been common worldwide. The rising incidence of these cancers has therefore promoted and contributed to the growth of the global market, as it is less invasive and more preferable.
Fluid biopsy, which is also known as liquid biopsy or fluid phase biopsy, is a procedure of sampling and analyzing non-solid biological tissues (blood and others), for the screening of cancer and other inflammatory conditions, associated with cardiac and other medical disorders.
Breast Cancer is Expected to Grow with High CAGR in the Forecasted Period
Breast cancer is the most common cancer among women and is the leading cause of mortality. It accounts for 12% of new cases of cancer being diagnosed every year. Incidence rates vary greatly worldwide. It is increasing, particularly in the developing countries, where a majority of the cases are diagnosed at later stages. Breast cancer is the most commonly diagnosed cancer among American women. About 1 in 8 American women develop invasive breast cancer, over the course of her lifetime. In 2016, an estimated 246,660 new cases of invasive breast cancer and 61,000 new cases of non-invasive (in situ) breast cancer were expected to be diagnosed among women in the United States.
Breast cancer is hormone related. Reproductive factors associated with prolonged exposure to endogenous estrogens, such as early menarche, late menopause, late age at first childbirth, etc. are among the most important risk factors for breast cancer. About 21% of all breast cancer deaths worldwide can be attributed to lifestyle factors, such as alcohol use, obesity, and physical inactivity. Early detection and treatment reduce the mortality rate. A biopsy is the only diagnostic procedure that can definitely determine if the suspicious area is cancerous. Breast biopsy test removes tissue or sometimes fluid from the suspicious area, and the removed cells are examined under a microscope and further tested, to check for the presence of breast cancer. Liquid biopsies are a reliable alternative to conventional biopsies, offering a potentially cheaper, easier, and less invasive way of monitoring malignancies. Patients can be tested more frequently. This method provides accurate results, as genetic sequencing of free-floating tumor DNA captures the diversity of genetic alterations found in cancer cells, in different parts of the body, including the primary tumor and metastases. Liquid biopsies could be used to guide cancer treatment decisions. Therefore, these tests are gaining traction, within the diagnostic industry. The fluid biopsy market is expected to boom and the increasing incidences of breast cancer is one of the driving factors for the growth. The various liquid biopsy platforms (circulating tumor cells (CTCs), and cell-free DNA (cfDNA), and exosomes) have shown a potential of adding tremendous value towards the care of breast cancer patients. Colorectal cancer and breast cancer together hold the major share of the fluid biopsy market.
North America Dominates the Market and Expected to do Same in the Forecast Period
North America is expected to dominate the overall market, throughout the forecast period. In North America region, the United States holds the largest market share and this is due to the fact that the cancer is the second most common cause of death in the United States which has helped the growth of the Fluid Biopsy market in the country.
The Fluid Biopsy market is competitive and consists of a few major players. In terms of market share, these major players currently dominate the market. Some of the major players of the market are Bio-Rad Laboratories, LungLife AI, Inc (Cynvenio), Guardant Health, Horizon Discovery, and Qiagen are among others.